


TRADUCCIÓN AL CASTELLANO DEL
CAPÍTULO REIVINDICATORIO CONCEDIDO EN LOS ESTADOS UNIDOS
(Procedimiento Acelerado de Examen de Patentes - PPH)

1. Un compuesto de la fórmula (I):



(I)

o una sal farmacéuticamente aceptable del mismo, en donde:

R¹ es un grupo opcionalmente sustituido seleccionado a partir de cicloalquilo C₃₋₈, heterociclilo de 5-8 miembros que contiene de 1 a 2 heteroátomos seleccionados a partir de N, O y S como miembros del anillo, fenilo, -SO₂-fenilo, -C(O)-fenilo, -C(R⁸)₂-fenilo, y un anillo de heteroarilo de 5-6 miembros, en donde estos heterociclilo y heteroarilo contienen de 1-2 heteroátomos seleccionados a partir de N, O y S como miembros del anillo,

y en donde los sustituyentes opcionales para R¹ son de 1-3 grupos independientemente seleccionados a partir de D, halo, hidroxilo, amino, -N(R⁸)₂, CN, alquilo C₁₋₄, alcoxilo C₁₋₄, -S-(alquilo C₁₋₄), haloalquilo C₁₋₄, haloalcoxilo C₁₋₄, cicloalquilo C₃₋₆, heterociclilo de 3-6 miembros que contiene de 1-2 heteroátomos seleccionados a partir de N, O, y S, oxo (excepto en los anillos aromáticos), CN, COOR⁸, CON(R⁸)₂, -NR⁸-C(O)R⁸, -NR⁸-C(O)OR⁸, -SO₂R⁸, -NR⁸SO₂R⁸, y SO₂N(R⁸)₂, en donde cada R⁸ es independientemente H o alquilo C₁₋₄;

L es un enlace, o L seleccionado a partir de alquilenilo C₁₋₄, alquenilenilo C₂₋₄, alquinilenilo C₁₋₄, cicloalquilo C₃₋₆ o un heterociclilo de 4-7 miembros que contiene de 1-2 heteroátomos seleccionados a partir de N, O y S como miembros del anillo, en donde L está opcionalmente sustituido con 1-3 grupos independientemente seleccionados a partir de R¹¹, D, OH, NH₂, -NHR¹¹, -NHC(=O)R¹¹, -NHC(=O)-OR¹¹, -NHC(=O)-NH₂, -NHC(=O)-NHR¹¹, -N(R¹¹)₂, CN, halo, N₃, CON(R⁷)₂, y COOR⁷; en donde cada R¹¹ es

independientemente alquilo C_{1-4} , los cuales pueden estar sustituidos con hasta tres grupos independientemente seleccionados a partir de D, halo, OH, NH_2 , -NHMe, -NMe₂, -OP(O)(OH)₂ y O-alquilo C_{1-4} ;

X e Y se seleccionan independientemente a partir de H, D, halo, CN, amino, hidroxilo, alquilo C_{1-4} , haloalquilo C_{1-4} , alcoxilo C_{1-4} , y haloalcoxilo C_{1-4} ;

R^2 es H, alquilo C_{1-4} , o arilalquilo C_{1-2} , en donde el arilo y alquilo C_{1-4} están opcionalmente sustituidos con halo, CN, alquilo C_{1-4} , haloalquilo C_{1-4} , cicloalquilo C_{3-6} , alcoxilo C_{1-4} , haloalcoxilo C_{1-4} , o alquilsulfonilo C_{1-4} ;

o R^2 se puede ciclar con X para formar un anillo heterocíclico de 5-7 miembros que contiene de 1-2 heteroátomos seleccionados a partir de N, O y S fusionados con el anillo de fenilo con el que X está unido,

o R^2 se puede ciclar con L para formar un anillo heterocíclico de 5-7 miembros que contiene de 1-2 heteroátomos seleccionados a partir de N, O, y S,

en donde el anillo heterocíclico opcional formado por R^2 ciclándose con X, o por R^2 ciclándose con L, puede estar opcionalmente sustituido con uno o dos grupos independientemente seleccionados a partir de CN, halo, alquilo C_{1-4} , alcoxilo C_{1-4} , haloalquilo C_{1-4} , haloalcoxilo C_{1-4} , oxo, CN, COOR⁷, CON(R⁷)₂, y -SO₂R⁷;

cada R⁷ es independientemente H o alquilo C_{1-4} ;

Z es N o CR⁴;

R^4 es H, D, halo, alquilo C_{1-4} , haloalquilo C_{1-4} , o alcoxilo C_{1-4} ;

R^5 se selecciona a partir de -C(O)-R^{5a} y R^{5a}; en donde R^{5a} es un cicloalquilo C_{3-8} opcionalmente sustituido, cicloalqueno C_{3-8} , un anillo heterocíclico de 3-8 miembros saturado o insaturado que contiene de 1-2 heteroátomos seleccionados a partir de N, O, y S, fenilo, o un anillo de heteroarilo de 5-6 miembros que contiene de 1-3 heteroátomos seleccionados a partir de N, O, y S, en donde los sustituyentes opcionales para R^5 son de 1-4 grupos independientemente seleccionados a partir de D, halo, hidroxilo, amino, CN, alquilo C_{1-4} , alcoxilo C_{1-4} , haloalquilo C_{1-4} , hidroxialquilo C_{1-4} , haloalcoxilo C_{1-4} , cicloalquilo C_{3-6} , heterociclilo de 3-6 miembros que contiene de 1-2 heteroátomos seleccionados a partir de N, O, y S, oxo (excepto en los anillos aromáticos), CN, -COOR⁹, -C(O)R⁹, CON(R⁹)₂, -NR⁹C(O)R⁹, -NR⁹CO₂R⁹, -SO₂R⁹, -NR⁹SO₂R⁹, y -SO₂N(R⁹)₂, en donde cada R⁹ es independientemente H o alquilo C_{1-4} opcionalmente sustituido con 1-3 grupos

independientemente seleccionados a partir de D, halo, OH, NH₂, NHMe y NMe₂; y dos sustituyentes sobre los mismos átomos de carbono o los átomos de carbono adyacentes de R⁵ se pueden tomar juntos opcionalmente para formar un anillo de 5-6 miembros que puede ser saturado o aromático y contiene de 1-2 heteroátomos seleccionados a partir de N, O y S y puede estar opcionalmente sustituido con 1-2 grupos independientemente seleccionados a partir de D, Me, halo, OH, oxo, O(alquilo C₁₋₄), NH₂, alquilamino C₁₋₄, di-(alquilo C₁₋₄)-amino; y

R⁶ es H, D, halo, alquilo C₁₋₄, o haloalquilo C₁₋₄.

2. El compuesto de la Reivindicación 1, o una sal farmacéuticamente aceptable del mismo, en donde:

Z es N o CH;

R² es H o Me;

R⁵ se selecciona a partir de -C(O)-R^{5a} y R^{5a}; en donde R^{5a} se selecciona de cicloalquilo C₃₋₈, un anillo heterocíclico de 5-8 miembros que contiene de 1-2 heteroátomos seleccionados a partir de N, O, y S, fenilo, y un anillo de heteroarilo de 5-6 miembros, y está opcionalmente sustituido con 1-3 grupos independientemente seleccionados a partir de D, halo, CN, hidroxilo, alcoxilo C₁₋₄, alquilo C₁₋₄, haloalquilo C₁₋₄, hidroxialquilo C₁₋₄, haloalcoxilo C₁₋₄, -SO₂R', -N(R')₂, -NR'-C(O)-R', y -SO₂NR'₂, donde cada R' es independientemente H o alquilo C₁₋₄; y

R⁶ es H.

3. El compuesto de la Reivindicación 2, en donde R⁵ se selecciona a partir de -C(O)-R^{5a} y R^{5a}; en donde R^{5a} se selecciona a partir de fenilo, piridina, piridona, pirazina, piridazina, pirazol, triazol, tetrazol, tiazol, oxazol, imidazol, isotiazol, isoxazol, furano, y tiofeno, cada uno de los cuales está opcionalmente sustituido con uno o dos grupos seleccionados independientemente a partir de halógeno, D, CN, alquilo C₁₋₄, alcoxilo C₁₋₄, haloalquilo C₁₋₄, hidroxialquilo C₁₋₄, haloalcoxilo C₁₋₄, CN, COOR⁹, CON(R⁹)₂, y -SO₂R⁹, en donde cada R⁹ es independientemente H o alquilo C₁₋₄.

4. El compuesto de la Reivindicación 3, o una sal farmacéuticamente aceptable del

mismo, en donde R^5 se selecciona a partir de $-C(O)-R^{5a}$ y R^{5a} ; en donde R^{5a} es pirazol o triazol y está opcionalmente sustituido con 1-2 grupos independientemente seleccionados a partir de halo, CN, alquilo C_{1-4} , haloalquilo C_{1-4} , hidroxialquilo C_{1-4} , alcoxilo C_{1-4} , y haloalcoxilo C_{1-4} .

5. El compuesto de la Reivindicación 2, en donde R^5 se selecciona a partir de $-C(O)-R^{5a}$ y R^{5a} ; en donde R^{5a} se selecciona a partir de ciclobutilo, ciclopentilo, ciclohexilo, ciclohexenilo, tetrahidropirano, dihidropirano, tetrahidrofurano, oxetano, azetidina, pirrolidina, piperidina, piperazina, morfolina, tetrahidrotiopirano (tiaciclohexano), y tetrahidrotiofurano (tiaciclopentano), cada uno de los cuales está opcionalmente sustituido con 1-3 grupos seleccionados independientemente a partir de halógeno, D, CN, $N(R^9)_2$, hidroxilo, alquilo C_{1-4} , alcoxilo C_{1-4} , haloalquilo C_{1-4} , hidroxialquilo C_{1-4} , haloalcoxilo C_{1-4} , oxo, CN, $COOR^9$, $CON(R^9)_2$, $-NHC(O)R^9$, $-NHCOOR^9$, $-NHSO_2R^9$, y $-SO_2R^9$, en donde cada R^9 es independientemente H o alquilo C_{1-4} .


6. El compuesto de la Reivindicación 2, en donde R^1 es fenilo y está opcionalmente sustituido con uno a tres grupos independientemente seleccionados a partir de halo, D, CN, alcoxilo C_{1-4} , alquilo C_{1-4} , haloalquilo C_{1-4} , haloalcoxilo C_{1-4} , SR' , $-SO_2R'$, $-N(R')_2$, $-NR'-C(O)-R'$, y $-SO_2NR'_2$, en donde cada R' es independientemente H, alquilo C_{1-4} o haloalquilo C_{1-4} .

7. El compuesto de la Reivindicación 2 en donde R^1 es tiofeno, tiazol, piridina, pirimidina, pirazina o piridazina, y está opcionalmente sustituido con hasta tres grupos independientemente seleccionados a partir de halo, CN, alcoxilo C_{1-4} , alquilo C_{1-4} , haloalquilo C_{1-4} , haloalcoxilo C_{1-4} , $-SO_2R'$, $-N(R')_2$, $-NR'-C(O)-R'$, y $-SO_2NR'_2$, en donde cada R' es independientemente H o alquilo C_{1-4} .

8. El compuesto de la Reivindicación 1, o una sal farmacéuticamente aceptable del mismo, en donde L se selecciona a partir del grupo que consiste en: ciclopropan-1,1-diilo; ciclopropan-1,2-diilo; y $-CHR''$, en donde R'' es H, D, o alquilo C_{1-2} opcionalmente sustituido con hasta tres grupos independientemente seleccionados a partir de D, hidroxilo,

halo, amino, alquilamino C₁₋₂, di(alquilo C₁₋₂)amino, y alcoxilo C₁₋₂.

9. El compuesto de la Reivindicación 8, en donde L es:




en donde R'' es metilo, o etilo, y está opcionalmente sustituido con flúor, amino, hidroxilo, metilamino, etilamino, dimetilamino, -OP(O)(OH)₂, metoxilo o etoxilo.

10. El compuesto de la Reivindicación 1, o una sal farmacéuticamente aceptable del mismo, en donde R² y L se enlazan entre sí para formar un grupo heterocíclico seleccionado a partir de morfolina, piperidina, tiomorfolina, piperazina, y pirrolidina que se une a R¹ y también está opcionalmente sustituido con uno o dos grupos independientemente seleccionados a partir de alquilo C₁₋₄, alcoxilo C₁₋₄, oxo, CN, COOR⁷, CON(R⁷)₂, y -SO₂R⁷, en donde cada R⁷ es independientemente H o alquilo C₁₋₄.

11. El compuesto de la Reivindicación 1, en donde Y es H, metilo, o halo.

12. El compuesto de la Reivindicación 1, en donde X es H, o R² se cicla con X para formar un anillo heterocíclico de 5-7 miembros fusionado con el anillo de fenilo con el que X está unido.

13. El compuesto de la Reivindicación 1, el cual es de la fórmula IA:



en donde R^5 es pirazol, imidazol, isoxazol, isotiazol, oxazol, triazol, o tiazol, el cual puede estar sustituido con hasta dos grupos independientemente seleccionados a partir de D, F, Cl, CN, Me, OMe, Et, iPr, OEt, y CF_3 ;


Y es H, F, Cl, o Me;

R^{10} es H o $-CH_2-R^*$, en donde R^* es H, -OH, F, $-NH_2$, -NHMe, -NMe₂, -OP(O)(OH)₂, o -OMe; y

R^1 es fenilo o tienilo opcionalmente sustituido con 1-2 grupos independientemente seleccionados a partir de halo, CN, alquilo C₁₋₄, alcoxilo C₁₋₄, haloalquilo C₁₋₄, haloalcoxilo C₁₋₄, CN, COOR⁸, CON(R⁸)₂, -SMe, y -SO₂R⁸, en donde cada R⁸ es independientemente H o alquilo C₁₋₄;

o una sal farmacéuticamente aceptable del mismo.

14. El compuesto de la Reivindicación 1, el cual es de la fórmula IB:



(IB)

en donde R^5 es un éter cíclico de 4-7 miembros o cicloalquilo C₅₋₆, y R^5 puede estar sustituido con hasta cuatro grupos independientemente seleccionados a partir de D, F, Cl, CN, amino, NHMe, NMe₂, $-CH_2OH$, -NHC(O)Me, -NH COOMe, -NH SO₂Me, Me Et, OMe, OH, oxo, Et, iPr, OEt, CN, y CF_3 ;

Y es H, F, Cl, o Me;

R^{10} es H o $-CH_2-R^*$, en donde R^* es H, -OH, F, $-NH_2$, -NHMe, -OP(O)(OH)₂, -NMe₂, o -OMe; y

R^1 es fenilo opcionalmente sustituido con 1-2 grupos independientemente seleccionados a partir de halo, CN, alquilo C₁₋₄, alcoxilo C₁₋₄, haloalquilo C₁₋₄, haloalcoxilo C₁₋₄, CN, COOR⁸, CON(R⁸)₂, y -SO₂R⁸, en donde cada R⁸ es independientemente H o


alquilo C₁₋₄;









o una sal farmacéuticamente aceptable del mismo.









15. El compuesto de la Reivindicación 14, en donde R⁵ es ciclohexilo sustituido con 1-3 grupos independientemente seleccionados a partir de D, F, Cl, CN, amino, NHMe, NMe₂, Me, NHSO₂Me, NHCOMe, OMe, OH, Et, CN, -CH₂OH, y CF₃.









16. El compuesto de la Reivindicación 14, en donde R¹ es fenilo sustituido con 0, 1 o 2 grupos independientemente seleccionados a partir de F, Cl, Br, I, SMe, SO₂Me, y CH₃.









17. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:



















	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	











 (+/-)	
 (+/-)	
	
	











	
	
	
	









	
	
	
	









	
	
	
	







	
	
	
	









	
	
	
	
	









	
	
	
	
	









	
	
	
	









	
	
	
	








	
	
	









	
	
	
	







	
	
	
	







	
	
	
	









	
	
	
	







	
	
	
	







	
	
	
	









	
	
	









	
	
	









	
	
	
	









	
	
	









	
	
	









	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	



















	
	
	
	









	
	
	
	









	
	
	
	





























	
	
	
	









 <chem>CS(=O)(=O)c1ccc(cc1)CNC(=O)c2ccc(cc2)c3nc(N)nc(C4CCOCC4)c3</chem>	 <chem>Nc1nc(NC2CC(O)CC2)c3ccc(cc3C(=O)N[C@@H](c4ccc(I)cc4)O)c1</chem>
 <chem>Nc1nc(NC2CCOCC2)c3ccc(cc3C(=O)NCCc4ccccc4)c1</chem>	 <chem>Nc1nc(NC2CC(O)CC2)c3ccc(cc3C(=O)N[C@@H](c4ccc(I)cc4)O)c1</chem>
 <chem>Nc1nc(NC2CCOCC2)c3ccc(cc3C(=O)N[C@@H](c4ccc(I)cc4)O)c1</chem>	 <chem>Nc1nc(NC2CC(O)CC2)c3ccc(cc3C(=O)N[C@@H](c4ccc(I)cc4)O)c1</chem>
 <chem>Nc1nc(NC2CCOCC2)c3ccc(cc3C(=O)N[C@@H](c4ccc(I)cc4)O)c1</chem>	 <chem>Nc1nc(NC2CC(O)CC2)c3ccc(cc3C(=O)N[C@@H](c4ccc(I)cc4)O)c1</chem>









	
	
	
	









	
	
	
	









	
	
	
	







	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	



















	
	
	
	









	
	
	
	









	
	
	
	









	
	
	
	




	
	
	
	


18. Una composición farmacéutica, la cual comprende un compuesto de la Reivindicación 1, mezclado con cuando menos un excipiente farmacéuticamente aceptable y que comprende además un co-agente terapéutico seleccionado a partir de compuestos contra el cáncer, analgésicos, y compuestos anti-inflamatorios.

19. Un método de tratamiento de cáncer, el cual comprende administrar a un sujeto que necesite dicho tratamiento, una cantidad terapéuticamente efectiva de un compuesto de la Reivindicación 1.


20. El método de la Reivindicación 19, en donde el cáncer se selecciona a partir de adenoma, adenoma, cáncer de vejiga, cáncer de cerebro, cáncer de mama, cáncer cervical, cáncer colo-rectal, cáncer de colon, carcinoma epidérmico, carcinoma folicular, cánceres genitourinarios, glioblastoma, cánceres de cabeza y cuello, enfermedad de Hodgkin, linfoma no de Hodgkin, hepatoma, cáncer de riñón, cánceres de pulmón, tales como cáncer pulmonar microcelular o no microcelular, leucemias, tales como leucemia mieloblástica aguda (AML)

o leucemia mieloblástica crónica (CML), mieloma múltiple, trastornos linfoides, cánceres de piel incluyendo melanoma, neuroblastoma, cáncer de ovario, cáncer pancreático, cáncer de próstata, cáncer rectal, sarcoma, cáncer testicular, y cáncer de tiroides.


21. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:




22. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:




23. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:




24. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:




25. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:




26. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:



27. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:



28. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:



29. Un compuesto, o una sal farmacéuticamente aceptable del mismo, seleccionado de:

